Here are the top 5 CURE stories for July 2019.
Here are the top 5 CURE stories for July 2019.
5. If Only We Could Freeze Time
Sometimes, life is good and you just want to hit the pause button to enjoy it as much as you can. Here, CURE contributor Jane Biehl writes about how her partial remission makes her want to “freeze time” and prevent change from happening.
4. Biosimilar Approval Offers Options in Blood Cancer
In this story, we cover the FDA’s approval of Ruxience, which could offer a more affordable treatment option for patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
3. A Patient-Turned-Caregiver Shares Her Story
Karen, who received a bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later. Learn more about her experience in this piece.
2. FDA Calls for Breast Implants to Be Recalled
After much debate, earlier this month the FDA requested that the manufacturer of a certain type of implant recall the product to protect women from potential risks, including breast implant-associated lymphoma. Read more in this breaking news coverage.
1. Life Is for Living
Have an adventure, buy the shoes and eat the cake. Here, a patient with glioblastoma shares her thoughts on why she doesn’t let a terminal diagnosis keep her from living her life.
Shannen Doherty Gives a Cancer Update, ‘Kool & the Gang’ Member Dies From Cancer and More
December 1st 2023As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.
Read More
‘The Complete Guide to Breast Reconstruction’ Author Empowers Patients With Information
October 5th 2023Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.
Listen
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).
Read More